A phase 1/2 clinical trial has shown a potential therapeutic impact of TLR9 inhibition on ABC DLBCL bearing MYD88 L265P mutation targeting TLR9 by an inhibitor referred as IMO-8400 in patients with relapsed or refractory DLBCL. Here, TLR9 is linked to diffuse large B-cell lymphoma.